News | July 31, 2024
Boehringer Ingelheim acquires Nerio Therapeutics for US$ 1.3bn
Boehringer Ingelheim aims to develop this program as a potential key centerpiece component for its immuno-oncology portfolio
Boehringer Ingelheim aims to develop this program as a potential key centerpiece component for its immuno-oncology portfolio
The discussion at the fourth session was centered on the fusion of academic rigor and industrial pragmatism as a key to pioneering solutions for sustainable and prosperous future
Kwality Pharma already has registration of 20 molecules from the units and 20 are under registration
Acquisition to expand Lilly's immunology pipeline with oral integrin therapies
New data on the secondary endpoint shows up to 52.3% of adults with fibrosis stages F1, F2 and F3 had improvement in fibrosis due to MASH
Oligonucleotides are a unique modality with potential to address hard-to-treat diseases with high unmet need
The state-of-the-art facility is equipped with best-in-class equipment and control systems
Outlook 2024 remains flat CER sales growth and CORE EBITDA margin of high 20s
New advanced technology-enabled offering aims to streamline synthetic route identification for novel active pharmaceutical ingredients (APIs)
One form of thalidomide has the intended sedative effect but the opposite mirror-image form interferes with foetal development
Subscribe To Our Newsletter & Stay Updated
